| jaks@jansons.id.au 2005-08-22, 8:46 am |
| Preliminary observations using HIV-specific transfer factor in AIDS.
Biotherapy 1996;9(1-3):41-7 (ISSN: 0921-299X) Pizza G; Chiodo F;
Colangeli V; Gritti F; Raise E; Fudenberg HH; De Vinci C; Viza D
Immunodiagnosis and Immunotherapy Unit, Ospedale S. Orsola-Malpighi,
Bologna, Italy. Twenty five HIV-1-infected patients, at various stages
(CDC II, III and IV) were treated orally with HIV-1-specific transfer
factor (TF) for periods varying from 60 to 1870 days. All patients were
receiving antiviral treatments in association with TF. The number of
lymphocytes, CD4 and CD8 subsets were followed and showed no
statistically significant variations. In 11/25 patients the number of
lymphocytes increased, whilst in 11/25 decreased; similarly an increase
of the CD4 lymphocytes was observed in 11/25 patients and of the CD8
lymphocytes in 15/25. Clinical improvement or a stabilized clinical
condition was noticed in 20/25 patients, whilst a deterioration was
seen in 5/25. In 12/14 anergic patients, daily TF administration
restored delayed type hypersensitivity to recall antigens within 60
days. These preliminary observations suggest that oral HIV-specific TF
administration, in association with antiviral drugs, is well tolerated
and seems beneficial to AIDS patients, thus warranting further
investigation.
For more info on TF visit www.healthandhabitat.com
|